skip to main content

Lipoprotein(a) Risk Assessment — EECC MCQ

Instant feedback + full explanation. One question, done properly.

ModerateCoronary Artery DiseaseLipoprotein(a) Risk AssessmentEECC

A 55-year-old man with a history of MI 2 years ago is on aspirin 75 mg, atorvastatin 80 mg, ramipril 10 mg, and bisoprolol 5 mg. His LDL-C is 1.2 mmol/L. He asks about further risk reduction. His Lp(a) is measured at 180 nmol/L (elevated). What is the significance?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Elevated Lp(a) is an independent, genetically determined cardiovascular risk factor not reducible by statins; it identifies patients at higher residual risk who may benefit from emerging Lp(a)-lowering therapies currently in clinical trials

Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein particle consisting of an LDL-like particle covalently bound to apolipoprotein(a). Elevated Lp(a) (>50 mg/dL or >125 nmol/L) is an independent, causal risk factor for ASCVD and aortic valve stenosis, affecting approximately 20% of the population. Critically, Lp(a) is NOT significantly reduced by statins, ezetimibe, or lifestyle measures. PCSK9 inhibitors reduce Lp(a) by ~25-30%. Dedicated Lp(a)-lowering antisense therapies (olpasiran, pelacarsen) are in Phase III trials (Lp(a)HORIZON). The 2019 ESC/EAS Dyslipidaemia Guidelines recommend measuring Lp(a) at least once in every person's lifetime to identify those with very high levels (>180 mg/dL) who may have lifetime ASCVD risk equivalent to heterozygous FH.

Reference: ESC/EAS (2019/2025): Dyslipidaemia Guidelines